MARKET PROFILE: Mongolia - Pharma’s Final Frontier?
This article was originally published in PharmAsia News
Mongolia is a country with a huge territory but relatively small population. In recent years, the country has developed rapidly because of its massive coking coal and copper deposits, with GDP growth of 7.8% in 2014. But what are the features, prospects and challenges for its healthcare industry?
You may also be interested in...
Clinical Trials: Industry Navigating Alternative Ways Of Delivering Investigational Drugs During Pandemic
New approaches include delivering study drug from a clinical site directly to a patient’s house through a courier service, as well as use of drones and automated dispensing units; future trials could see a mix of delivery approaches.
Benefits of the BCMA-directed antibody-drug conjugate outweigh its ocular risks in heavily pretreated multiple myeloma patients, Oncologic Drugs Advisory Committee says at the conclusion of a virtual meeting beset by technical problems.
The FDA must report to the House Appropriations Committee on any work toward defining “natural” cosmetics and on the health effects of talc, asbestos and lead in cosmetic products. The committee’s 2021 FDA spending bill report also cites concerns about skin-lightening products containing “dangerous levels of mercury and hydroquinone.”